Albert CM, Ma J, Rifai N, et al. Prospective study of c-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-99. (Class C) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002;288:2998-3007. (Class A) Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapys – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106. (Class M) Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis: the Leiden intervention trial. N Engl J Med 1985;312:805-11. (Class B) Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64:369-77. (Class A) Backman JT, Kyrklund C, Kivistö KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-29. (Class A) Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64. (Class R) Berg A, Frey I, Baumstark MW, et al. Physical activity and lipoprotein lipid disorders. Sports Med 1994;17:6-21. (Class R) Bild DE, Williams RR, Brewer HB, et al. Identification and management of heterozygous familial hypercholesterolemia: summary and recommendations from an NHLBI workshop. Am J Cardiol 1993;72:1D-5D. (Class R) Billimoria JD, Pozner H, Metselaar B, et al. Effect of cigarette smoking on lipids, lipoproteins, blood coagulation, fibrinolysis and cellular components of human blood. Artherosclerosis 1975;21:61-76. (Class C) Blankenhorn DH, Johnson RL, Mack WJ, et al. The influence of diet on the appearance of new lesions in human coronary arteries. JAMA 1990;263:1646-52. (Class B) Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73:3D-11D. (Class R) Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92. (Class A) Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002;112:298-304. (Class M) Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995;92:2419-25. (Class M) Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. JACC 1986;8:1245-55. (Class A) Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. (Class A) Carlson LA, Rosenhamer G. Reduction in mortality in the Stockholm ischemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18. (Class A) Cheung MC, Zhao XQ, Chait A, et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001;21:1320-26. (Class A) Coronary Drug Project Research Group, The. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81. (Class A) Criqui MH. The reduction of coronary heart disease with light to moderate alcohol consumption: effect or artifact? Br J Addict 1990;85:854-57. (Class R) Denke MA. Revisiting the effectiveness of the National Cholesterol Education Program's Step I and Step II Diets: cholesterol-lowering diets in a pharmaceutically driven world. Am J Clin Nutr 1999;69:581-82. (Class R) Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22. (Class A) Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-97. (Class C) Durrington PN, Bhatnager D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001;85:544-48. (Class A) Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-10. (Class M) Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA 2000;284:1263-70. (Class A) Evans M, Rees A. The myotoxicity of statins. Current Opinion in Lipidology 2002;13:415-20. (Class R) Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45. (Class A) Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91. (Class C) GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-55. (Class A) Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998;98:2513-19. (Class A) Goldstein JL, Brown MS. Familial hypercholesterolemia. In The Metabolic Basis of Inherited Disease. Scriver CS, Blaudet AL, Sly WS, et al., eds. New York: McGraw-Hill, 1989:1215-51. (Class R) Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997;31:859-63. (Class R) Grundy SM. Consensus statement: role of therapy with ‘statins' in patients with hypertriglyceridemia. Am J Cardiol 1998;81:1B-6B. (Class R) Grundy SM. Stanol esters as a component of maximal dietary therapy in the national cholesterol education program adult treatment panel III report. J Cardiol 2005;96:47D-50D. (Class R) Guay DRP. Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother 1999;33:1083-103. (Class R) Gylling H, Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in hyper cholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia 1994;37:773-80. (Class C) Gylling H, Radhakrishan R, Miettinnen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine. Circulation 1997;96:4226-31. (Class A) Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-91. (Class A) Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. preventive services task force. Ann Intern Med 2002;136:161-72. (Class M) Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. (Class A) HIT Trial. (Class A) Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317-25. (Class R) Jackson R, Beaglehole R. The relationship between alcohol and coronary heart disease: is there a protective effect? Curr Opin Lipidol 1993;4:21-26. (Class R) Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83:687-700. (Class R) Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens 2006;8:35-41. (Class R) Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-82. (Class A) Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43. (Class A) Klatsky AL, Friedman GD, Siegelaub AB. Alcohol and mortality: a 10-year Kaiser-Permanente experience. Ann Intern Med 1981;95:139-45. (Class B) Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57. (Class R) LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid-lowering with atorvastatin in patients with stable coronary artery disease. New Engl J Med 2005;352:1425-35. (Class A) LaRosa JC, Jiang H, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-46. (Class M) Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54:585-94. (Class M) Levy D. A multifactorial approach to coronary disease risk assessment. Clin Exp Hypertens 1993;15:1077-86. (Class R) Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64. (Class A) LIPID Study Group, The. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349-57. (Class A) Lovastatin-Erythromycin. In Evaluation of Drug Interactions. Zucchero F, ed. Hearst Corporation, Dec 1997. 18/12.05-18/12.05a. (Class R) McBride PE. The health consequences of smoking: cardiovascular diseases. Med Clin North Am 1992;76:333-53. (Class R) McKenney J. Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. Am J Cardiol 2002;90:8K-20K. (Class R) McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol 2006;97:89C-94C. (Class R) McKenney JM, Hawkins DW. Lipid modifying drugs. In Handbook on the Management of Lipid Disorders 2nd Edition. Richmond, VA: National Pharmacy Cholesterol Council, 2001a;124-41. (Class R) McKenney JM, Hawkins DW. Management of lipid disorders. In Handbook on the Management of Lipid Disorders 2nd Edition. Richmond, VA: National Pharmacy Cholesterol Council, 2001b. (Class R) McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19:689-98. (Class A) Miettinen TA, Puska H, Gylling H, et al. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. New Engl J Med 1995;333:1308-12. (Class A) Morris L, Schulz RM. Medication compliance: the patient's perspective. Clin Ther 1993;15:593-606. (Class R) Mosca L, Appel LJ, Benjamin EJ. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-93. (Class R) Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999;138:151-55. (Class D) Mymin D, Dembinski T, Friesen MH. Iatrogenic severe depression of high-density lipoprotein cholesterol. J Clin Pharmacol 2009;49:865-71. (Class D) National Cholesterol Education Program. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) National Institutes of Health. 2001. (Class R) Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc 2000;40:475-85. (Class R) Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80. (Class A) Normén L, Frohlich J, Montaner J, et al. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004;27:2241-42. (Class D) Nowak SN, Jaber LA. Aspirin dose for prevention of cardiovascular disease in diabetics. Ann Pharmacother 2003;37:116-21. (Class R) Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129-33. (Class A) Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-16. (Class A) Phillips LS, Branch Jr WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-34. (Class R) Physicians' Health Study Research Group, Steering Committee of the. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129-35. (Class A) Pignone M, Phillips C, Mulrow C. Use of lipid-lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321:1-5. (Class M) Pronk NP. Short term effects of exercise on plasma lipids and lipoproteins in humans. Sports Med 1993;16:431-48. (Class R) Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280-87. (Class C) Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207. (Class A) Riesen WF, Darioli R, Noll G. Lipid-lowering therapy: strategies for improving compliance. Curr Med Res Opin 2004;20:165-73. (Class R) Rimm EB, Klatsky A, Grobbee D, et al. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits? BMJ 1996;312:731-36. (Class R) Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91. (Class A) Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56. (Class A) Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-89. (Class A) Scheffler E, Wiest E, Woehrle J, et al. Smoking influences the atherogenic potential of low-density lipoprotein. Clin Investig 1992;70:263-68. (Class C) Schrott HG, Stein EA, Dujovne CA, et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol 1995;75:34-39. (Class A) Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet: effects on progression of coronary artery disease. Circulation 1992;86:1-11. (Class A) Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolemia. BMJ 1991;303:893-96. (Class B) Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial – lipid-lowering arm (ASCOT–LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58. (Class A) Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17. (Class R) Shepherd J, Blauw GJ, Murphy BM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30. (Class A) Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-07. (Class A) Stalenhoef AFH, de Graaf J, Wittekoek ME, et al. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrigliceridemia. Artherosclerosis 2000;153:129-38. (Class A) Stefanick ML, Mackey S, Sheehan M, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL-cholesterol and high levels of LDL-cholesterol. N Engl J Med 1998;339:12-20. (Class A) Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994;78:117-41. (Class R) Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23. (Class R) Taylor PA, Ward A. Women, high-density lipoprotein cholesterol, and exercise. Arch Intern Med 1993;153:1178-84. (Class R) Thompson GR, Seed M, Niththyananthan S, et al. Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis 1989;9(suppl I):I75-I80. (Class R) Vanhanen HT, Blomqvist S, Enholm C, et al. Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment. J Lipid Res 1993;34:1535-44. (Class A) Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80. (Class R) West of Scotland Coronary Prevention Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-45. (Class A) Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:155-68. (Class R) Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996;334:1298-1303. (Class D) Williams PT. Relationship of distance run per week to coronary heart disease risk factors in 8,283 male runners. Arch Intern Med 1997;157:191-98. (Class D) Williams RR, Hasstedt SJ, Wilson DE, et al. Evidence that men with familial hypercholesterolemia can avoid early coronary death. JAMA 1986;255:219-24. (Class D) Yamamoto A, Kamiya T, Yamamura T, et al. Clinical features of familial hypercholesterolemia. Arteriosclerosis 1989;9(suppl I):I66–I74. (Class D)
|